China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
The new season has brought a change in line-up for some companies with new hires and retirements, but for some it meant changing the rules to keep key players.